C7A.010
BillableMalignant carcinoid tumor of the duodenum
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C7A.010 an HCC code?
Yes. C7A.010 maps to Lymphoma and Other Cancers under the CMS-HCC V28 risk adjustment model (and Breast, Prostate, and Other Cancers and Tumors under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C7A.010
For C7A.010to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C7A.010 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C7A.010 is the ICD-10-CM diagnosis code for malignant carcinoid tumor of the duodenum. A rare type of cancer that starts in hormone-producing cells of the duodenum (the first part of the small intestine). This tumor grows and spreads to other parts of the body. C7A.010 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neuroendocrine tumors (c7a).
Under the CMS-HCC V28 risk adjustment model, C7A.010 maps to Lymphoma and Other Cancers (HCC 21) with a community, non-dual, aged base RAF weight of 0.671. Under the older CMS-HCC V24 model, C7A.010 maps to Breast, Prostate, and Other Cancers and Tumors (HCC 12) with a community, non-dual, aged base RAF weight of 0.150. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Carcinoid tumors are neuroendocrine tumors; ensure you have documentation confirming the malignant nature and duodenal location before coding C7A.010. Because C7A.010 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C7A.010 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Carcinoid tumors are neuroendocrine tumors; ensure you have documentation confirming the malignant nature and duodenal location before coding C7A.010
- •This code is specific to the duodenum—verify the exact anatomical site in the pathology report, as carcinoid tumors in other small intestine locations use different codes (C7A.011 for jejunum, C7A.012 for ileum)
Clinical Significance
Malignant carcinoid tumor of the duodenum is a rare neuroendocrine neoplasm of the first segment of the small intestine. Duodenal carcinoids may be functional (producing hormones like gastrin or somatostatin) or non-functional, and are often discovered incidentally during upper endoscopy. They have variable malignant potential depending on size, grade, and local invasion.
Documentation Requirements
- ✓Pathological confirmation of neuroendocrine differentiation and malignant grade — Ki-67 index, mitotic rate
- ✓Specific location within the duodenum — first through fourth portions
- ✓Tumor size — critical for prognosis (tumors >2 cm have higher metastatic potential)
- ✓Depth of invasion — mucosal, submucosal, or transmural
- ✓Assessment for functional hormone production — gastrin, somatostatin levels
- ✓Staging workup — CT, octreotide scan for metastatic disease
Commonly Confused Codes
- •C17.0 — Primary malignant neoplasm of duodenum; adenocarcinoma of the duodenum is histologically different from carcinoid
- •C7A.011 — Malignant carcinoid tumor of jejunum; ensure the tumor is in the duodenum, not the jejunum
- •C7A.019 — Malignant carcinoid tumor of small intestine, unspecified; use C7A.010 when duodenum is confirmed
- •D3A.010 — Benign carcinoid tumor of duodenum; verify malignant versus benign behavior